Janssen's heritage in neuroscience began more than 60 years ago, when our namesake, Dr. Paul Janssen, developed a drug that revolutionized the standard of care for schizophrenia.
Our medications and innovations have improved quality of care for millions of patients living with neuropsychiatric conditions. In fact, three of our medicines are on the WHO Essential Medicines List.
Today, we are committed to maintaining innovative R&D that solves for unmet needs across psychiatric conditions. We have maintained our portfolio of long-acting injectables for schizophrenia; developing treatments for difficult-to-treat depression subpopulations; and improving the symptoms and time-to-relapse for patients living with these conditions.